Tags

Type your tag names separated by a space and hit enter

Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease.
Neurobiol Aging 2006; 27(12):1763-8NA

Abstract

Upregulation of a number of chemokines, including monocyte chemotactic protein-1 (MCP-1), is associated with Alzheimer's disease (AD) pathological changes. Emerging evidence suggests that inflammatory events precede the clinical development of AD, as cytokine disregulation has been observed also in patients with mild cognitive impairment (MCI). MCP-1 levels were evaluated in serum samples from 48 subjects with MCI, 94 AD patients and 24 age-matched controls. Significantly increased MCP-1 levels were found in MCI and mild AD, but not in severe AD patients as compared with controls. mRNA levels in peripheral blood mononuclear cells (PBMC), evaluated by quantitative RT-PCR analysis, paralleled serum MCP-1 levels. Moreover, a progressive MCP-1 decrease was observed over a 1-year follow up in a subgroup of MCI subjects converted to AD. MCP-1 upregulation is likely to be a very early event in AD pathogenesis, by far preceding the clinical onset of the disease. Nevertheless, as MCP-1 is likely to play a role in several pathologies with an inflammatory component, a possible usefulness as an early AD biomarker would be possible only in combination with other molecules.

Authors+Show Affiliations

Department of Neurological Sciences, Dino Ferrari Center, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy. daniela.galimberti@unimi.it <daniela.galimberti@unimi.it>No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16307829

Citation

Galimberti, Daniela, et al. "Serum MCP-1 Levels Are Increased in Mild Cognitive Impairment and Mild Alzheimer's Disease." Neurobiology of Aging, vol. 27, no. 12, 2006, pp. 1763-8.
Galimberti D, Fenoglio C, Lovati C, et al. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging. 2006;27(12):1763-8.
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., ... Scarpini, E. (2006). Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiology of Aging, 27(12), pp. 1763-8.
Galimberti D, et al. Serum MCP-1 Levels Are Increased in Mild Cognitive Impairment and Mild Alzheimer's Disease. Neurobiol Aging. 2006;27(12):1763-8. PubMed PMID: 16307829.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. AU - Galimberti,Daniela, AU - Fenoglio,Chiara, AU - Lovati,Carlo, AU - Venturelli,Eliana, AU - Guidi,Ilaria, AU - Corrà,Barbara, AU - Scalabrini,Diego, AU - Clerici,Francesca, AU - Mariani,Claudio, AU - Bresolin,Nereo, AU - Scarpini,Elio, Y1 - 2005/11/22/ PY - 2005/06/17/received PY - 2005/09/21/revised PY - 2005/10/18/accepted PY - 2005/11/26/pubmed PY - 2007/1/4/medline PY - 2005/11/26/entrez SP - 1763 EP - 8 JF - Neurobiology of aging JO - Neurobiol. Aging VL - 27 IS - 12 N2 - Upregulation of a number of chemokines, including monocyte chemotactic protein-1 (MCP-1), is associated with Alzheimer's disease (AD) pathological changes. Emerging evidence suggests that inflammatory events precede the clinical development of AD, as cytokine disregulation has been observed also in patients with mild cognitive impairment (MCI). MCP-1 levels were evaluated in serum samples from 48 subjects with MCI, 94 AD patients and 24 age-matched controls. Significantly increased MCP-1 levels were found in MCI and mild AD, but not in severe AD patients as compared with controls. mRNA levels in peripheral blood mononuclear cells (PBMC), evaluated by quantitative RT-PCR analysis, paralleled serum MCP-1 levels. Moreover, a progressive MCP-1 decrease was observed over a 1-year follow up in a subgroup of MCI subjects converted to AD. MCP-1 upregulation is likely to be a very early event in AD pathogenesis, by far preceding the clinical onset of the disease. Nevertheless, as MCP-1 is likely to play a role in several pathologies with an inflammatory component, a possible usefulness as an early AD biomarker would be possible only in combination with other molecules. SN - 1558-1497 UR - https://www.unboundmedicine.com/medline/citation/16307829/Serum_MCP_1_levels_are_increased_in_mild_cognitive_impairment_and_mild_Alzheimer's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0197-4580(05)00336-2 DB - PRIME DP - Unbound Medicine ER -